Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.
- Citation:
- J Clin Oncol vol 41 (suppl 16) TPS11584
- Meeting Instance:
- ASCO 2023
- Year:
- 2023
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Kristine Lacuna Sumithra Mandrekar Jacob Allred Stephanie Berg Martee Hensley Gary K. Schwartz Matthew Ingham
- Networks:
- COLUMBIA, LAPS-MA036, LAPS-MN026, LAPS-NY016
- Study
- Alliance-A092104
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2/3
- Keywords: